Herceptin Phase III early adjuvant data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genentech halts two Phase III trials of Herceptin (trastuzumab) as adjuvant therapy in women with early HER2 positive breast cancer following positive interim results. A preliminary analysis of the National Cancer Institute-sponsored trials found Herceptin provided an improvement in the primary endpoint of disease-free survival as well as the secondary endpoint of overall survival. "We will work…to prepare these data for discussion with the FDA about a filing for Herceptin in the adjuvant setting based on this interim analysis," Genentech said. Novartis is planning an sNDA for use of Femara (letrozole) in the early adjuvant breast cancer setting in the second quarter (1Pharmaceutical Approvals Monthly February 2005, p. 5)...
You may also be interested in...
Herceptin early adjuvant sBLA
Genentech is requesting a priority review for its supplemental BLA for use of Herceptin (trastuzumab) in early adjuvant treatment of HER-2 positive breast cancer. Announced Feb. 15, the application includes data from two randomized Phase III trials showing that the addition of Herceptin to standard adjuvant therapy significantly reduced the risk of recurrence (1Pharmaceutical Approvals Monthly May 2005, In Brief)...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.